Market Signal Briefing

OMAHA, Neb.--(BUSINESS WIRE)--ACI Worldwide (NASDAQ: ACIW), an original innovator in global payments technology, today announced a strategic partnership with BitPay, the world’s leading cryptocurrency payments processor, to further expand its digital assets solutions for merchants and payment service providers (PSPs) through ACI's Payments Orchestration Platform.

Our partnership with BitPay represents one element of our broader digital assets strategy. Based on growing demand from our PSPs and merchant clients, we're ensuring they have multiple pathways to leverage these emerging rails where they add value.

Share
This partnership strengthens ACI’s commitment to digital currency innovation by expanding the platform’s established capabilities for merchants and PSPs. According to a recent study by ACI Worldwide and Payments Dive, 55% of global retailers are evaluating cryptocurrency acceptance as part of their payment strategy.

By integrating BitPay, ACI further differentiates its Payments Orchestration Platform, enabling seamless acceptance and management of digital currencies including stablecoins as a strategic complement to traditional payment rails. Building on capabilities ACI introduced in 2021, merchants and PSPs can now integrate BitPay, alongside other payment options to access upgraded features - including the ability to accept, store, and spend cryptocurrencies. BitPay's platform supports a range of use cases, including peer-to-peer payments, and mobile point-of-sale applications.

"As regulated stablecoins evolve from niche to mainstream, they're creating new opportunities for cross-border transactions and settlement optimization," said Adriana Iordan, Global Head of Merchant at ACI Worldwide. "Our partnership with BitPay represents one element of our broader digital assets strategy. Based on growing demand from our PSPs and merchant clients, we're ensuring they have multiple pathways to leverage these emerging rails where they add value - whether for payment acceptance or specific use cases like cross-border B2B settlements and treasury operations."

"Together with ACI Worldwide, we're making digital currencies more accessible and practical for real-world commerce," said Stephen Pair, Co-Founder and CEO at BitPay. "This partnership brings our proven crypto payment capabilities to ACI's global customer base, enabling everything from simple payment acceptance to cross-border settlement scenarios as market demand develops."

The integrated solution supports settlement in both fiat and stablecoins, offering enhanced flexibility and efficiency for merchants operating in diverse markets. As our clients explore these capabilities, businesses can leverage stablecoins for treasury operations, supplier payments, and cross-border settlements - creating new options for how global commerce can operate.

ACI's Payment Orchestration Platform streamlines the complexity of managing multiple payment methods, acquirers, and gateways through a single, unified interface. By incorporating various digital currency solutions, merchants and PSPs can explore new revenue opportunities - typically seeing a 1–3% percent growth in sales where implemented - while offering customers greater choice and convenience at checkout.

“ACI Worldwide remains committed to a rail-agnostic approach, expanding its digital assets ecosystem through additional partnerships and integrations as the market matures,” continued Adriana Iordan. “This ensures our clients are prepared to leverage digital payment innovations as use cases emerge and regulatory frameworks solidify.”

About ACI Worldwide

ACI Worldwide, an original innovator in global payments technology, delivers transformative software solutions that power intelligent payments orchestration in real time so banks, billers, and merchants can drive growth, while continuously modernizing their payment infrastructures, simply and securely. With 50 years of trusted payments expertise, we combine our global footprint with a local presence to offer enhanced payment experiences to stay ahead of constantly changing payment challenges and opportunities.

About BitPay

Founded in 2011, BitPay is one of the oldest cryptocurrency companies. As a pioneer in blockchain payment processing, the company's mission is to transform how businesses and people send, receive, and store money. Its business solutions eliminate fraud chargebacks, reduce the cost of payment processing, and enable borderless payments in cryptocurrency, among other services. For consumers, the BitPay Wallet offers a complete digital asset management solution to buy, store, swap, sell, and spend cryptocurrency with ease. The company has offices in North America, Europe, and South America and has raised more than $70 million in funding from leading investment firms including Founders Fund, Index Ventures, Virgin Group, and Aquiline Technology Growth. For more information visit bitpay.com.

© Copyright ACI Worldwide, Inc. 2025

ACI, ACI Worldwide, ACI Payments, Inc., ACI Pay, Speedpay and all ACI product/solution names are trademarks or registered trademarks of ACI Worldwide, Inc., or one of its subsidiaries, in the United States, other countries or both. Other parties’ trademarks referenced are the property of their respective owners.

The logo of German pharmaceuticals company Merck is seen at the company's headquarters in Darmstadt, Germany, May 16, 2016. REUTERS/Kai Pfaffenbach/File Photo Purchase Licensing Rights, opens new tab

Oct 16 (Reuters) - German pharmaceuticals and technology company Merck KGaA

(MRCG.DE), opens new tab slightly improved its mid-term guidance for its healthcare business ahead of its capital markets day on Thursday.

Merck now expects mid-term annual organic sales growth in the low- to mid single-digit percentage range for its healthcare business, having guided for "slight growth" last year. It expects mid-to-high single-digit percentage growth for Life Science, after guiding for 7% to 9% last year.

Sign up here.

The company also confirmed that it is aiming to achieve net sales between around 20.5 to 21.7 billion euros in 2025, a target it has cut twice this year.

This is far below the 25 billion euros the Darmstadt-based firm had previously guided for at its capital markets day in 2021.

"We had made a number of assumptions on the pandemic that never materialized," Merck's Chief Executive Belen Garijo said in an interview.

The company's life science business was affected by a "Covid cliff" where mRNA vaccines were not in demand for as long as expected, she said.

Reporting by Marleen Kaesebier, Patricia Weiss and Matthias Inverardi; editing by Matt Scuffham

Our Standards: The Thomson Reuters Trust Principles., opens new tab

SummaryChipotle aims to expand from 3,750 to over 7,000 North American locations and is pursuing international growth despite uncertain global demand for Mexican cuisine.CMG is improving operational efficiency with new staff roles and kitchen technology, enhancing customer service speed and employee retention.The company is piloting catering services, which could significantly boost profitability if scaled successfully without disrupting core operations.Risks include weaker lower-income consumer spending and potential stock market declines, which could impact CMG's sales and valuation. Anne Czichos/iStock Editorial via Getty Images

Introduction: Chipotle (NYSE:CMG) is an incredibly popular fast-casual restaurant chain that has taken the United States by storm over the past couple of years. I believe that, despite some near term headwinds such as

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in CMG over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two years1

eGFR is key marker of kidney function; IgAN is progressive autoimmune kidney disease that leads to kidney failure in many patients1-3 

Fabhalta is first and only approved complement inhibitor for adults with IgAN and has potential to delay disease progression4,5 

Fabhalta received accelerated approval for reduction of proteinuria in adults with IgAN in US in 2024; data support 2026 submission for traditional FDA approval4,5  Basel, October 16, 2025 – Novartis today announced positive final results from APPLAUSE-IgAN, a Phase III study evaluating Fabhalta® (iptacopan) in adults living with IgA nephropathy (IgAN). Fabhalta, an oral alternative complement pathway inhibitor, demonstrated statistically significant, clinically meaningful superiority compared to placebo in slowing IgAN progression measured by annualized total slope of estimated glomerular filtration rate (eGFR) decline over two years1.  

“Progressive diseases such as IgAN present an urgent need for interventions that can ultimately improve kidney health. Many people with IgAN commonly experience fear and anxiety of disease progression,” said Ruchira Glaser, Development Unit Head, Cardiovascular, Renal & Metabolic, Novartis. “We are excited about today’s positive Phase III APPLAUSE-IgAN results showing slowed eGFR decline, which add to the growing evidence of Fabhalta as a targeted therapy to preserve long-term kidney function, giving hope to people living with this condition.” 

Novartis intends to use these data to support Fabhalta submissions in 2026. Alongside Fabhalta, Novartis continues to advance its multi-asset IgAN portfolio, which also includes Vanrafia® (atrasentan) and investigational compound zigakibart.

IgAN is a progressive autoimmune kidney disease with approximately 25 per million people newly diagnosed worldwide each year3. IgAN is highly debilitating as it leads to glomerular inflammation, proteinuria, and a gradual decline in eGFR2. Up to 50% of patients with persistent proteinuria progress to kidney failure within 10 to 20 years of diagnosis, often requiring dialysis or kidney transplantation as part of long-term disease management2,6,7. Furthermore, people living with IgAN often face mental, social, and economic challenges2,8. Supportive care does not address the underlying causes of the disease and often fails to slow disease progression, reinforcing the need for more targeted therapies for IgAN3,9.

In APPLAUSE-IgAN, Fabhalta was well tolerated with a favorable safety profile in line with previously reported data10. Full data from the APPLAUSE-IgAN final analysis will be presented at future medical meetings.

About Fabhalta® (iptacopan) 
Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway10.

Discovered at Novartis, Fabhalta received US Food and Drug Administration (FDA) and European Commission (EC) approval in December 2023 and May 2024, respectively, for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). Fabhalta also received accelerated approval in the US in August 2024, and in China in September 2025, for the reduction of proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease progression (generally UPCR ≥1.5 g/g4,5,11,12. In 2025, Fabhalta received FDA and EC approval as well as approvals in China and Japan for the treatment of adults with C3 glomerulopathy (C3G), making it the first treatment approved for this condition13-15. 

Fabhalta is being studied in a broad range of rare kidney diseases, including atypical hemolytic uremic syndrome (aHUS), immune complex membranoproliferative glomerulonephritis (IC-MPGN) and lupus nephritis (LN)16-18. Studies are ongoing to evaluate the safety and efficacy profiles in these investigational indications and support potential regulatory submissions16-18. 

About APPLAUSE-IgAN 
APPLAUSE-IgAN (NCT04578834) is a Phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of twice-daily oral Fabhalta (200 mg) in 477 adult primary IgAN patients (main study population). Patients were randomized to Fabhalta or placebo, on top of supportive care (a stable dose of maximally-tolerated renin-angiotensin system (RAS) inhibitor therapy with or without a stable dose of SGLT2i)1.    

The two primary endpoints of the study for the interim and final analysis, respectively, are proteinuria reduction at 9 months as measured by UPCR, and the annualized total eGFR slope over 24 months10,18. During the final analysis, the following secondary endpoints were assessed: proportion of participants reaching UPCR <1 g/g without receiving corticosteroids/immunosuppressants or other newly approved drugs or initiating new background therapy for treatment of IgAN or initiating kidney replacement therapy (KRT), time from randomization to first occurrence of composite kidney failure endpoint event (reaching either sustained ≥30% decline in eGFR relative to baseline or sustained eGFR <15 mL/min/1.73 m2 or maintenance dialysis or receipt of kidney transplant or death from kidney failure), and change from baseline to 9 months in the fatigue scale measured by the Functional Assessment Of Chronic Illness Therapy-Fatigue questionnaire19.    

The main study population enrolled patients with an eGFR ≥30 mL/min/1.73 m2 and UPCR ≥1 g/g at baseline10,18. In addition, a smaller cohort of patients with severe renal impairment (eGFR 20–30 mL/min/1.73 m2 at baseline) was also enrolled to provide additional information but not contributing to the main efficacy analyses10,19. 
    
Novartis commitment to kidney diseases 
Building on a 40-year legacy that began in transplant, Novartis is on a mission to empower breakthroughs and transform care in kidney health, starting with kidney conditions that have significant unmet need.  

Historically, these conditions have had considerably less funding and research, leading to a treatment landscape largely focused on reactive or end-stage disease management, often with significant physical, emotional, and financial burdens. Our portfolio targets the underlying causes of disease, with an aim to protect kidney health and delay or prevent dialysis and/or transplantation. Our goal is to help patients get back to living life on their terms - whether at work, in school, or with loved ones, and by partnering with patients, advocates, clinicians and policymakers, we aim to raise awareness, accelerate diagnosis and get patients the right care, sooner.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis 
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

References

Novartis. Data on file. Kwon CS, Daniele P, Forsythe A et al. A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of immunoglobulin a nephropathy. J Health Econ Outcomes Res 2021;8:36–45. Cheung C, Barratt J. The rapidly changing treatment landscape of IgA nephropathy. Semin Nephrol 2025;44:151573. Novartis Pharmaceuticals Corporation. Fabhalta prescribing information. 2023 (2025 update). Available at: https://www.novartis.com/us-en/sites/novartis_us/files/fabhalta.pdf (accessed October 2025). Novartis Pharmaceuticals Corporation. Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN) (2024). Available at: https://www.novartis.com/news/media-releases/novartis-receives-fda-accelerated-approval-fabhalta-iptacopan-first-and-only-complement-inhibitor-reduction-proteinuria-primary-iga-nephropathy-igan (accessed October 2025). Pitcher D, Braddon F, Hendry B et al. Long-term outcomes in IgAN. Clin J Am Soc Nephrol 2023;18:727–8.Mohd R, Mohammad Kazmin NE, Abdul Cader R, et al. Long-term outcome of immunoglobulin A (IgA) nephropathy: a single center experience. PLoS One. 2021;16:e0249592. National Kidney Foundation. The voice of the patient (2020). Available at: https://igan.org/wp-content/uploads/2021/01/VOP_IgAN_12-7-20__FNL.pdf (accessed October 2025).Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100:S1–276. Perkovic V, Barratt J, Rovin B, et al. Alternative complement pathway inhibition with iptacopan in IgA nephropathy. N Engl J Med. 2025;392:531–543.Fabhalta®. EMA Summary of Product Characteristics. Novartis Europharm Limited (2024). Available at: https://www.ema.europa.eu/en/documents/product-information/fabhalta-epar-product-information_en.pdf (accessed October 2025). PHARMCUBE. Novartis expands indications for iptacopan, capmatinib in China (2025). Available at: Novartis Expands Indications for Iptacopan, Capmatinib in China PharmCube-News & Reports (accessed October 2025). Fineline Cube. Novartis’ fabhalta approved in China for C3 glomerulopathy (2025). Available at: Novartis' Fabhalta Approved in China for C3 Glomerulopathy - Insight, China's Pharmaceutical Industry (accessed October 2025). Pharma Japan. Novartis makes full foray into nephrology space with fabhalta: exec (2025). Available at: Novartis Makes Full Foray into Nephrology Space with Fabhalta: Exec | PHARMA JAPAN (accessed October 2025).Novartis. Press release. Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) (2025). Available at: https://www.novartis.com/news/media-releases/novartis-receives-third-fda-approval-oral-fabhalta-iptacopan-first-and-only-treatment-approved-c3-glomerulopathy-c3g (accessed October 2025). Clinicaltrials.gov. NCT04889430. Efficacy and Safety of Iptacopan (LNP023) in Adult Patients with Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy (APPELHUS). Available at: https://clinicaltrials.gov/study/NCT04889430 (accessed October 2025).  Clinicaltrials.gov. NCT05755386. Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN (APPARENT). Available at: https://clinicaltrials.gov/study/NCT05755386 (accessed October 2025). Clinicaltrials.gov. NCT05268289. Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/ - V. Available at: https://clinicaltrials.gov/study/NCT05268289 (accessed October 2025). Rizk DV, Rovin BH, Zhang H et al. Targeting the alternative complement pathway with iptacopan to treat IgAN: design and rationale of the APPLAUSE-IgAN study. Kidney Int Rep 2023;8:968–79.  # # #

SummaryI believe Palantir's UK strategic partnership should catalyze international government growth from future NATO and European MoD wins.Considering the momentum in the number of deals announced since PLTR's last earnings season (7 at the moment of writing this article), I see a high-probability Q3 and FY25 beat.Despite robust US commercial growth, international commercial revenue remains weak, hindered by EU AI regulations and a lack of new deals.I am now ultra-bullish on PLTR, expecting the company to outperform Street estimates in Q3 and maintain its upward trajectory. merc67/iStock via Getty Images

In my last coverage on Palantir Technologies Inc. (NASDAQ:PLTR) (NEOE:PLTR:CA), I was quite cautious with my bull thesis, given that I estimated that 76% of cRPO depends on cancelable sub-12-month contracts.

Since then, I've been keeping

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Elon Musk’s one-word reply on X has put Bitcoin back in the headlines, even if the comment was brief. His simple response — “True” — came after a widely shared post linking recent gains in gold, silver and Bitcoin to heavy government spending and currency debasement. Markets and crypto fans noticed fast.

Musk’s Brief Reply Signals Interest
According to the post by ZeroHedge, which has more than 2 million followers, the rallies were tied to what the author called an AI “arms race” between the US and China and to large-scale fiscal outlays.

Musk agreed with the thread. He added a view that echoes a common pro-Bitcoin line: fiat can be printed, while Bitcoin’s tie to energy gives it a different kind of backing. That single-word answer reopened a conversation many thought had cooled.

The money is not the problem: AI is the new global arms race, and capex will eventually be funded by governments (US and China). If you want to know why gold/silver/bitcoin is soaring, it’s the “debasement” to fund the AI arms race.

But you can’t print energy https://t.co/qwdD8QbVON

— zerohedge (@zerohedge) October 14, 2025

True.

That is why Bitcoin is based on energy: you can issue fake fiat currency, and every government in history has done so, but it is impossible to fake energy.

— Elon Musk (@elonmusk) October 14, 2025

Tesla’s Past Moves And Holdings
Based on reports, Tesla bought $1.5 billion of Bitcoin in early 2021 and said it would take the coin as payment for cars. But the deal was short-lived.

The company soon stopped accepting Bitcoin because of concerns about mining’s heavy energy use and said it might resume payments only after a major move toward renewable mining practices.

By mid-2022, Tesla sold about 75% of its holdings, a move that happened near a market low and drew wide notice. According to Arkham Intelligence, Tesla still holds roughly 11,509 BTC, which is worth about $1.25 billion at current prices.

BTCUSD now trading at $111,517, Chart: TradingView
What The Market Might Be Watching
Traders read signals. A single public endorsement from a high-profile executive used to move prices more. That was the case in 2021 when Tesla’s investment and payment plan helped lift sentiment.

Now, the context is different. Crypto markets are bigger and more diverse, and a one-word message does not equal a corporate decision. No official change at Tesla has been reported, and company spokespeople have not confirmed any shift in strategy.

Featured image from ET Edge Insights, chart from TradingView

Leading cryptocurrencies fell on Wednesday, but stocks recovered, as the Trump administration remained resolute in its stance against China.

CryptocurrencyGains +/-Price (Recorded at 9:30 p.m. ET)Bitcoin (CRYPTO: BTC)-1.48%$110,900.78Ethereum (CRYPTO: ETH)
               -2.29%$3,995.86XRP (CRYPTO: XRP)                         -3.41%$2.41Solana (CRYPTO: SOL)                         -4.15%$194.27Dogecoin (CRYPTO: DOGE)                         -3.37%$0.1969Crypto Market FaltersBitcoin meandered in the $111,000 region as trading volume declined sharply. Spot exchange-traded funds linked to the asset recorded net outflows of more than $90 million on Oct. 15, according to SoSo Value.

Ethereum dipped below $4,000 but found good support in the $3,900 zone. Trading volume declined 27% over the last 24 hours. XRP and Dogecoin also edged lower.

Cryptocurrency liquidations reached $442 million in the last 24 hours, with nearly $400 million in long positions wiped out from the market, according to Coinglass. That said, nearly $500 million in BTC shorts risked liquidation if the asset rebounds to $115,000

Bitcoin’s open interest declined 1.77% in the last 24 hours, and more than 23% since the all-time highs hit earlier this month.

"Fear" sentiment continued to define the market, according to the Crypto Fear & Greed Index.

Top Gainers (24 Hours) 

Cryptocurrency (Market Cap>$100 M)Gains +/-Price (Recorded at 9:30 p.m. ET)Bless (BLESS)     +591.90%$0.2165BNB Attestation Service (BAS)    
               +56.14%$16.65ChainOpera AI (COAI )          +19.48%$0.7964The global cryptocurrency market capitalization stood at $3.75 trillion, following a decrease of 2.24% in the last 24 hours.

Stocks Rebound, Gold StrengthensThe stock market bounced back on Wednesday. The S&P 500 gained 0.4% to close at 46,253.31, while the tech-focused Nasdaq Composite ended up 0.7% at 22,670.08. The Dow Jones Industrial Average inched lower, sliding 17.15 points, or 0.04%, to end at 46,253.31.

The recovery came despite Treasury Secretary Scott Bessent stating that the recent sell-offs won't deter Washington from taking "strong measures" against China.

Last week, Trump threatened "100% tariffs" on China over its "aggressive" stance on export controls, sending stocks and cryptocurrencies crashing.

Meanwhile, gold continued its record-breaking run, surging past $4,200 per ounce.

Why ETH Should Hold This LevelWidely followed cryptocurrency analyst and trader Ali Martinez highlighted $3,900 as a "major support zone" for Ethereum.

"Iff it holds, the Pricing Bands point to a move toward $5,000 or even $6,000," Martinez predicted.

The Market Value Realized Value Deviation Pricing Bands model price levels based on deviations from its realized price and help identify market cycle tops and bottoms.

Blockchain analytics firm CryptoQuant said that Bitcoin has moved into the later stage of its bull cycle, with long-term investors booking profits while short-term holders taking control. 

"The key signal to watch next will be a decline in short-term holder share, which would mark the start of a renewed accumulation phase led by long-term investors," CryptoQuant added.

Photo Courtesy: Travis Wolfe on Shutterstock.com

Read Next:    

Bitcoin, Ethereum, Tesla On 5x Steroids: VolatilityShares Seeks SEC Approval For Its Wildest Ride Yet
Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

3 mins mins

Key Points:

UK authorities seized 61,000 BTC in major fraud case.$6.8 billion Bitcoin scam victims await compensation plan.Legal debates continue over Bitcoin fund retention or compensation.
British prosecutors announced plans to compensate victims of Zhimin Qian’s nearly $7 billion Bitcoin scam in China, seized by UK authorities between 2018 and 2021.

The case highlights ongoing legal debates over asset allocation in fraud scandals, with potential impacts on international regulatory practices and crypto market stability.

UK Seizes 61,000 BTC in Historic Recovery Amid Scam
In a major development, authorities in the United Kingdom are preparing to offer compensation to victims of a significant Bitcoin scam that defrauded over 128,000 individuals in China. During the period from 2014 to 2017, Zhimin Qian orchestrated a series of fraudulent investment schemes, converting the ill-gotten gains into nearly $7 billion worth of Bitcoin.

Bitcoin valued at $6.8 billion, or 61,000 BTC, has been seized, marking one of the largest asset recovery cases globally. The UK government is currently deliberating on the use of these assets, which may support victim restitution or be retained under specific asset forfeiture laws.

Reactions to the case have sparked considerable debate. Jackson Ng, representing investors, emphasized the importance of prioritizing victims’ compensation in light of the substantial assets involved. Meanwhile, Nick Harris of CryptoCare has expressed concerns that UK authorities might keep the funds, potentially frustrating expectations for compensation.

Jackson Ng, Legal Representative, stated, “We are prioritizing victim compensation, though the specifics of the plan are still to be determined.” – source
Bitcoin Price and Legal Proceedings Stir Market Concerns
Did you know? The seizure of 61,000 BTC in the Zhimin Qian case surpasses the historic Silk Road BTC recovery, setting a new precedent in asset seizure operations globally.

Bitcoin (BTC), currently priced at $111,436.30, shows a market cap of $2.22 trillion. With a 24-hour trading volume of $70.73 billion, the BTC market faced a decrease of 1.58% over the last day, as reported by CoinMarketCap. Its 90-day price change reflects a loss of 7.26% amidst these developments.

Bitcoin(BTC), daily chart, screenshot on CoinMarketCap at 02:26 UTC on October 16, 2025. Source: CoinMarketCap

Coincu analysts note the ongoing legal proceedings could influence regulatory approaches towards crypto asset retention and redistribution. Past cases show assets are typically retained, raising questions on future compensation guidelines and jurisdictional asset management. For more insights, UK prosecutors pursuing compensation plan for record Bitcoin seizure offers additional context. The case also accentuates the need for a robust legal framework to manage such seizures, as highlighted by similar scenarios discussed in analyses like this report on Bitcoin trends.

DISCLAIMER: The information on this website is provided as general market commentary and does not constitute investment advice. We encourage you to do your own research before investing.

Rate this post

Coinbase has revealed plans to list BNB on its platform as part of its listing roadmap.

Massive DOJ seizure, $1.3B wallet move, and 401(k) bill fuel bullish rebound — Bitcoin price prediction eyes $130K breakout.

Journalist

Posted: October 16, 2025

Key Takeaways
What’s driving Zcash’s rebound?
ZEC rose 12% after Open Interest hit $237 million, signaling renewed leverage activity and strong retail buying pressure.

How high can it go?
Sustained demand above $250 could push ZEC past $300, with momentum building toward its $391 all-time high.

Zcash [ZEC] rebounded sharply over the past 24 hours, gaining 12% from its recent dip at press time, and reignited investor attention.

The daily chart showed that the broader trend remained bullish, with $298 as the next key resistance target.

In fact, the Stochastic RSI approached the oversold zone near 30, hinting that the latest rebound could mark the end of the short-term correction.

That left traders watching whether ZEC’s bullish spark could evolve into a sustained rally.

Source: TradingView

Leverage piles up as Open Interest hits $237M
According to data from Coinalyze, ZEC’s Open Interest (OI) climbed by 10% in the past day, reaching $237 million.

The uptick reflected a surge in leveraged positions and speculative inflows, a familiar sign of traders rushing to capitalize on short-term momentum.

From the previous observations, such spikes tend to precede volatile phases as markets adjust to overextended leverage, making the next few sessions critical for ZEC’s direction.

Source: Coinalyze

At the same time, ZEC retail traders have been particularly active, driving liquidity and fueling optimism across exchanges.

Accumulation clusters formed around current price levels, suggesting that smaller investors were fueling liquidity. That behavior mirrored previous altcoin rallies, where early retail inflows typically preceded larger institutional entries.

If ZEC sustains its current accumulation, the altcoin could attract institutional attention once again.

Source: CryptoQuant

Spot strength vs. speculative fragility
While the momentum looked promising, the sustainability of ZEC’s move hinges on more than short-term enthusiasm.

For your understanding, leverage-driven rallies can quickly lose steam if they lack follow-through from spot market buyers or long-term holders.

Data from CryptoQuant showed both Spot Taker CVD and Futures Taker CVD in Taker Buy Dominant territory, confirming active demand.

Yet, sustained upside required deeper participation from whales and institutions.

Source: CryptoQuant

On top of that, maintaining support around the breakout zone remained critical. A strong defense there could keep momentum intact toward $300.

If OI and spot demand continue rising together, ZEC could retest $300 and possibly aim for its next psychological mark near $391, its all-time high.

Ethereum price is still struggling to settle above $4,220. ETH is now consolidating in a range and might decline sharply if there is a move below $3,880.

Ethereum started a recovery wave above the $4,000 and $4,020 levels.
The price is trading below $4,050 and the 100-hourly Simple Moving Average.
There is a short-term contracting triangle forming with support at $3,950 on the hourly chart of ETH/USD (data feed via Kraken).
The pair could continue to move up if it trades above $4,075.

Ethereum Price Dips To Support
Ethereum price struggled to settle above $4,200 and corrected most gains, like Bitcoin. ETH price declined below the $4,050 and $4,000 levels.

It even tested the $3,940 zone. A low was formed at $3,932 and the price is now consolidating losses. There was a minor increase above the 23.6% Fib retracement level of the recent decline from the $4,216 swing high to the $3,932 low.

Besides, there is a short-term contracting triangle forming with support at $3,950 on the hourly chart of ETH/USD. Ethereum price is now trading below $4,050 and the 100-hourly Simple Moving Average.

On the upside, the price could face resistance near the $4,075 level. The next key resistance is near the $4,150 level and the 76.4% Fib retracement level of the recent decline from the $4,216 swing high to the $3,932 low. The first major resistance is near the $4,200 level.

Source: ETHUSD on TradingView.com
A clear move above the $4,200 resistance might send the price toward the $4,250 resistance. An upside break above the $4,250 region might call for more gains in the coming sessions. In the stated case, Ether could rise toward the $4,350 resistance zone or even $4,420 in the near term.

Another Decline In ETH?
If Ethereum fails to clear the $4,150 resistance, it could start a fresh decline. Initial support on the downside is near the $3,950 level and the triangle’s trend line. The first major support sits near the $3,880 zone.

A clear move below the $3,880 support might push the price toward the $3,820 support. Any more losses might send the price toward the $3,750 region in the near term. The next key support sits at $3,640.

Technical Indicators

Hourly MACD – The MACD for ETH/USD is losing momentum in the bullish zone.

Hourly RSI – The RSI for ETH/USD is now below the 50 zone.

Major Support Level – $3,950

Major Resistance Level – $4,150

The company said it has since burned the excess tokens, and that the root cause of the incident has been addressed.

Ethereum could be one step closer to achieving 10,000 transactions per second, following the introduction of a new Ethereum scaling technology called Pico Prism. 

Ethereum scaling firm Brevis announced on Wednesday a new state-of-the-art zero-knowledge Ethereum Virtual Machine (zkEVM) for real-time proving. 

The technology can now prove Ethereum blocks almost instantly using regular retail gaming processors (GPUs) instead of expensive supercomputers.

“Brevis has achieved real-time proving of Ethereum L1 using consumer-grade hardware,” the firm stated, adding that it used 64 Nvidia RTX 5090 graphics cards, the current flagship model for gaming. 

In a test conducted in September, Pico Prism achieved 99.6% real-time proving in under 12 seconds. Real-time proving (RTP) means generating a cryptographic proof that a block was executed correctly faster than new blocks are being produced.

“This marks a major step toward scaling Ethereum by 100x and a future where you can validate the chain from a phone.”Pico Prism has turbocharged real-time proving. Source: Brevis
Brevis has a roadmap to achieve 99% real-time proving with fewer than 16 RTX 5090 GPUs “in the next couple of months.”

Big step toward Ethereum scalingThis breakthrough means that proving, which is computationally expensive, has finally caught up to block production speed using affordable consumer hardware, which makes lightweight validation practical for the first time.

Currently, every validator re-executes every transaction to verify blocks, which requires expensive hardware and creates a fundamental bottleneck, Brevis explained.

“Real-time proving breaks this model. One prover generates a proof, and everyone else verifies it in milliseconds.”The path to 10,000 TPSAccording to the Ethereum roadmap, validators will switch from re-executing transactions to simply verifying ZK-proofs, enabling the base layer to hit 10,000 transactions per second.

“At 3x per year, scaling Ethereum L1 would reach 10k TPS by April 2029,” said Ryan Sean Adams from Bankless. 

Ethereum’s Fusaka upgrade, expected in December, will simplify real-time proving, explained Bitcoin security researcher Justin Drake.

“EIP-7825 caps per transaction gas usage, enabling more parallel proving via subblocks,” he said before adding, “By year’s end, several teams will prove every L1 EVM block on a 16-GPU cluster, drawing less than 10kW total.”

Phone as a node future It is “one big step toward Ethereum’s future,” said the Ethereum Foundation, which added: 

“ZK technology like Pico Prism will enable Ethereum to scale to meet global demand, while still remaining trustworthy and decentralized.”“The phone-as-a-node future just got real,” said tech entrepreneur Mike Warner. 

Ethereum is transforming into a zk-chain, said Adams, who explained that layer-1 will run global DeFi, with big blocks at 10,000 TPS, and nodes that run on a phone, while layer-2 will run everything else.

It is essentially the holy grail of blockchain: massive scalability without sacrificing decentralization or security.

Magazine: Ethereum’s roadmap to 10,000 TPS using ZK tech: Dummies’ guide

Ethereum’s high-timeframe structure exposes the fallout from the leverage massacre. Open Interest has cratered, reflecting widespread liquidation across futures markets. With leverage drained and traders shaken out, the path forward depends on whether spot demand can fill the vacuum left by the OI collapse.

The recent market volatility has presented a critical opportunity to assess the underlying health of various crypto assets. In an X post, Daan Crypto Trades, a full-time crypto trader and investor, has offered a compelling analysis of Ethereum’s high-timeframe chart, specifically focusing on Open Interest (OI), which shows exactly how much speculative excess has been washed out. Particularly, ETH got hit hard in the process.

Why This Flush Could Be The Foundation For Ethereum’s Next Move
According to Daan, what’s encouraging is that ETH’s Open Interest is now sitting at levels comparable to when ETH traded at $3,000. Meanwhile, the price now hovers around $4,000. For Daan, a simple rule of thumb to determine whether a healthy reset has occurred is if open interest is lower than it was previously at a specific price. 

Typically, as price increases, Open Interest tends to rise as more capital flows into derivative markets, and vice versa. This relative comparison of OI and price is crucial because an increase or decrease in price will generally make OI trend in both directions. 

There are also coins used as margin, which can inflate OI figures in a rising market. Thus, the relative levels to watch out for are between OI and price, which carry more weight than the absolute numbers.

Source: Chart from Daan Crypto Trades on X
In the meantime, leverage is making a comeback in the Ethereum market. As the Master of Crypto, an observer of market dynamics, has highlighted, the Open Interest on ETH has surged 8.2% within 24 hours, fueling the ongoing price move. The surge in Open Interest suggests that traders are once again opening aggressive long positions after the recent flush, a familiar pattern that often carries more risk than reward.

Master of Crypto advises caution, framing this leverage-driven rally within a historical context, that approximately 75% of rallies aggressively fueled by such a rapid build-up in leverage tend to reverse, while only 25% sustain their momentum upward.

The Calm Phase Before The Next Expansion
The Ethereum macro trend remains upward despite the short-term move. Analyst EtherNasyonaL has emphasized that after breaking free from its long-standing downtrend, ETH is currently only retesting the demand zone and trendline, a healthy bullish move retest that is typical of a strong market structure.

However, the analyst pointed out that the fluctuation on the short timeframes doesn’t define the trend, but it’s the longer timeframes that hold the true directional signal. Currently, “ETH macrotrend is still upward, and the bigger picture hasn’t yet spoken.”

ETH trading at $4,101 on the 1D chart | Source: ETHUSDT on Tradingview.com
Featured image from Pixabay, chart from Tradingview.com

Gambardello identifies three downside Cardano levels after $0.90 trendline rejection.
Mid-$0.60s around $0.62 marks lowest target if bearish trend continues.
Fibonacci support levels could trigger reversal if defended by buyers.

Market analyst Dan Gambardello has outlined three downside price targets for Cardano following rejection from a lower trendline retest. The analysis comes as ADA continues declining alongside broader cryptocurrency market weakness.

Cardano corrected 3% on Thursday, extending losses after failing to reclaim support around $0.90 earlier this month. The token has now lost both the 20-day and 50-day moving averages, creating conditions for further downside testing.

CRYPTO'S Massive Momentum Signal Is Building Into 2026 (REPEAT MOVE)

Intro 00:00
Perspective 00:10
Crypto momentum 1:40
Ethereum targets 6:15
Cardano targets 9:10 pic.twitter.com/gzHda2TLhm

— Dan Gambardello (@cryptorecruitr) October 9, 2025

Gambardello’s analysis identifies multiple support levels that could come into play if bearish momentum persists. The lowest target sits in the mid-$0.60 range, specifically around $0.62, which represents a key support area.

Technical breakdown could trigger deeper decline
The analyst acknowledged he does not want to see prices reach the lowest target but maintained it represents the technical objective following a price breakdown. The $0.62 level would mark a critical test of support if current weakness continues.

While emphasizing caution due to clear bearish trend signals, Gambardello did not completely rule out potential for price recovery. He outlined conditions under which a bullish reversal could materialize.

Current Fibonacci support levels will determine whether buyers can halt the decline. A rebound from these technical zones would establish foundations for retesting the lower trendline where rejection occurred earlier in October.

Cardano’s reaction upon reaching the trendline would prove decisive for determining market direction. A successful breakout above this level would signal bullish momentum returning for moves toward higher prices.

Another rejection at the trendline would confirm it functions as resistance, likely resulting in sideways trading rather than upward continuation. This scenario would maintain the current consolidation pattern without establishing clear directional bias.

Key reversal level identified at $0.87
Gambardello highlighted $0.87 as a critical level for bulls to reclaim. Movement toward this price point would constitute a positive development for Cardano’s technical structure.

Successfully reclaiming $0.87 could mark the beginning of reversal momentum according to the analyst’s framework. This level sits above current prices but below the contested $0.90 trendline.

The three-target approach provides specific levels for traders to monitor as Cardano navigates current market conditions. Each support zone represents potential areas where buyers could emerge to defend against further losses.

Current price action suggests ADA remains vulnerable to additional downside testing before establishing a sustainable bottom. The identified Fibonacci support levels will determine whether the decline extends to lower targets or reverses from current areas.

Seasoned Crypto Content Writer, Editor and Journalist who entered the cryptocurrency industry out of sheer passion and love for writing.

Coinbase has revealed its plans to list BNB (Binance Coin) once it completes the required technical infrastructure and market-making arrangements. This would be the first time the exchange supports a token that originated from the Binance ecosystem, signaling a potential shift in its listing strategy.

The announcement follows the earlier launch of BNB perpetual futures on Coinbase’s international and advanced trading platforms. These futures contracts allow traders to hold BNB derivative positions indefinitely, which served as a preparatory move before enabling spot trading.

Assets added to the roadmap today: BNB (BNB)https://t.co/lyEugQo7Cv

— Coinbase Markets 🛡️ (@CoinbaseMarkets) October 15, 2025

According to Coinbase’s updated roadmap, the BNB listing will go live only after the exchange ensures sufficient liquidity from market makers and finalizes its internal trading systems. The company is also expanding its support for more networks and ecosystems, aiming to increase asset availability and strengthen its competitive positioning.

At the time of the announcement, BNB was trading around $1,168, showing a 4.3 percent decline over the past 24 hours but maintaining a strong 27 percent gain over the month. This reflects growing investor confidence despite short-term market corrections.

The development comes amid ongoing discussions in the crypto industry about listing fees and conditions on major exchanges. Some community members have claimed that new projects often face high listing costs, including token deposits or promotional allocations. Binance has denied such claims, maintaining that it does not charge direct listing fees and that any deposits are refundable.

Prominent figures such as Arthur Hayes, co-founder of BitMEX, have previously alleged that exchange listing demands can include a small portion of token supply or staking commitments as part of onboarding requirements. While these claims remain debated, they highlight the complex dynamics behind new asset listings on centralized exchanges.

If Coinbase successfully integrates BNB trading, it could significantly expand access for retail and institutional investors while enhancing liquidity and strengthening cross-exchange competition. Analysts believe the move could also pave the way for broader interoperability between competing ecosystems.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. Cryptocurrency investments are volatile and risky. Always conduct your research before making any investment decisions.

Hiren is a SEO Expert and content writer with a passion for all things cryptocurrency. With two years of experience in the Crypto industry, He has a wealth of knowledge about blockchain technology and the crypto market. He is always on the lookout for new and exciting blockchain projects to work on and is dedicated to helping these projects succeed in the ever-evolving crypto landscape.

Scan QR code to install app

Important DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your own due diligence checks, apply your own discretion and consult your competent advisors. The content of the website is not personally directed to you, and we does not take into account your financial situation or needs.The information contained in this website is not necessarily provided in real-time nor is it necessarily accurate. Prices provided herein may be provided by market makers and not by exchanges.Any trading or other financial decision you make shall be at your full responsibility, and you must not rely on any information provided through the website. FX Empire does not provide any warranty regarding any of the information contained in the website, and shall bear no responsibility for any trading losses you might incur as a result of using any information contained in the website.The website may include advertisements and other promotional contents, and FX Empire may receive compensation from third parties in connection with the content. FX Empire does not endorse any third party or recommends using any third party's services, and does not assume responsibility for your use of any such third party's website or services.FX Empire and its employees, officers, subsidiaries and associates, are not liable nor shall they be held liable for any loss or damage resulting from your use of the website or reliance on the information provided on this website.Risk DisclaimersThis website includes information about cryptocurrencies, contracts for difference (CFDs) and other financial instruments, and about brokers, exchanges and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and come with a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money.FX Empire encourages you to perform your own research before making any investment decision, and to avoid investing in any financial instrument which you do not fully understand how it works and what are the risks involved.

NEW ORLEANS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 20, 2025 to file lead plaintiff applications in a securities class action lawsuit against Snap Inc. (NYSE: SNAP), if they purchased the Company’s securities between April 29, 2025 to August 5, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.

Get Help

Snap investors should visit us at https://claimsfiler.com/cases/nyse-snap-2/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

Snap and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On August 5, 2025, the Company announced its financial results for the second quarter of fiscal 2025, disclosing a deceleration in advertising revenue growth due to “an issue related to our ad platform, the timing of Ramadan and the effects of the de minimis changes.”

On this news, the price of Snap’s shares fell from a closing price of $9.39 per share on August 5, 2025 to $7.78 per share on August 6, 2025, a decline of about 17.15% in the span of just a single day.  

The case is Abdul-Hameed v. Snap, Inc., et al., No. 25-cv-07844.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

NEW ORLEANS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 21, 2025 to file lead plaintiff applications in a securities class action lawsuit against C3.ai, Inc. (“C3” or the “Company”) (NYSE: AI), if they purchased the Company’s securities between February 26, 2025 to August 8, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.

Get Help

C3 investors should visit us at https://claimsfiler.com/cases/nyse-ai-2/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

C3 and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On August 8, 2025, the Company disclosed disappointing preliminary financial results for 1Q 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing its poor sales results and lowered guidance to “the reorganization with new leadership” as well as the health ailments of its Chief Executive Officer.

On this news, the price of C3’s shares fell from a closing price of $22.13 per share on August 8, 2025 to $16.47 per share on August 11, 2025, a decline of about 25.58%.  

The case is John Liggett Sr. v. C3.ai, Inc., et al., No. 25-cv-07129.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

NEW ORLEANS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against V.F. Corporation. (NYSE: VFC), if they purchased or otherwise acquired VFC securities between October 30, 2023 and May 20, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Colorado.

Get Help

V.F. Corporation investors should visit us at https://www.claimsfiler.com/cases/nyse-vfc or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

V.F. and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On May 21, 2025, the Company announced its fourth quarter and full-year fiscal 2025 results, disclosing a significant decline in its Vans brand growth trajectory, which decreased from an 8% loss the quarter before to a 20% loss in the fourth quarter, and noting such decline would continue through the next quarter, largely due to “a direct effect of deliberately reduced revenue to eliminate unprofitable or unproductive businesses” and “an additional set of deliberate actions” already in place but previously unannounced.

On this news, the price of V.F.’s shares fell from a closing price of $14.43 per share on May 20, 2025 to $12.15 per share on May 21, 2025, a decline of about 15.8% in the span of just a single day.

The case is Brenton v. V.F. Corporation, No. 25-cv-02878.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

NEW ORLEANS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Fluor Corporation (NYSE: FLR), if they purchased or otherwise acquired the Company’s securities between February 18, 2025 and July 31, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Texas.

Get Help

Fluor investors should visit us at https://claimsfiler.com/cases/nyse-flr-2/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

Fluor and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On August 1, 2025, the Company announced its financial results for the second quarter of 2025, disclosing a Q2 non-GAAP EPS of $0.43, missing consensus estimates by $0.13, and revenue of $3.98 billion, representing a 5.9% year-over-year decline and missing consensus estimates by $570 million due to growing costs in multiple infrastructure projects due to subcontractor design errors, price increases, and scheduling delays, as well as reduced capital spending by customers. The Company also disclosed a negatively revised financial outlook for FY 2025, guiding to adjusted EBITDA of $475 million to $525 million, down significantly from Defendants' prior guidance of $575 million to $675 million, and adjusted EPS of $1.95 per share to $2.15 per share, down significantly from Defendants' prior guidance of $2.25 per share to $2.75 per share.

On this news, the price of Fluor’s shares fell $15.35 per share, or 27.04%, to close at $41.42 per share on August 1, 2025.  

The case is Maglione v. Fluor Corporation, et al., No. 25-cv-02496.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

NEW ORLEANS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 17, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cytokinetics, Incorporated (NasdaqGS: CYTK), if they purchased or otherwise acquired the Company’s securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.

Get Help

Cytokinetics investors should visit us at https://www.claimsfiler.com/cases/nasdaq-cytk or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

Cytokinetics and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On March 10, 2025, the Company disclosed that the U.S. Food and Drug Administration (“FDA”) had decided not to convene an advisory committee meeting to review the Company’s New Drug Application (“NDA”) for its aficamten product. Then, on May 6, 2025, the Company disclosed that it had held multiple pre-NDA meetings with the FDA discussing safety monitoring and risk mitigation but chose to submit the NDA without a Risk Evaluation and Mitigation Strategy, instead relying on labeling and voluntary education materials.

On this news, the price of Cytokinetics’ shares fell, closing at $33.04 per share on May 7, 2025.  

The case is Seidman v. Cytokinetics, Incorporated, et al., No. 25-cv-07923.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

NEW ORLEANS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 8, 2025 to file lead plaintiff applications in a securities class action lawsuit against WPP plc (NYSE: WPP), if they purchased or otherwise acquired the Company’s shares between February 27, 2025 and July 8, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.

Get Help

WPP investors should visit us at https://claimsfiler.com/cases/nyse-wpp/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

WPP and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On July 9, 2025, the Company published a trading update for the first half of 2025, disclosing that it had allegedly “seen a deterioration in performance as Q2 has progressed” due to both “continued macro uncertainty weighing on client spend and weaker net new business than originally anticipated,” as well as “some distraction to the business” as a result of the continued restructuring of WPP Media a.k.a. GroupM. The Company further disclosed that its CEO “will retire from the Board and as CEO on 31 December 2025.”

On this news, the price of WPP’s shares fell from a closing price of $35.82 per share on July 8, 2025 to $29.34 per share on July 9, 2025, a decline of about 18.1% in the span of just a single day.

The case is Marty v. WPP plc, 25-cv-08365.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

U.S. President Donald Trump said Wednesday that Indian Prime Minister Narendra Modi told him New Delhi will stop buying oil from Russia, though the move will take time.

"[Modi] assured me today that they will not be buying oil from Russia. That's a big stop." Trump said at the press briefing in the Oval Office. "Now we've got to get China to do the same thing."

He added that Washington was unhappy with New Delhi's purchases of Russian crude because it allowed Moscow to continue waging its "ridiculous war" in Ukraine.

However, the U.S. president also said that the halt will not be immediate, and there will be "a little bit of a process," without giving a clear timeline.

CNBC reached out to India's Ministry of Petroleum and Natural Gas for comment, but did not receive an immediate reply.

India's imports of Russian oil have been a sticking point in the relationship between Washington and New Delhi. Trump slapped additional tariffs of 25% on India back in August, raising the total levy to 50%, while India has called out the U.S. for its trade with Russia.

"If India doesn't buy [Russian] oil, it makes [ending the war] much easier," Trump said. "They assured me within a short period of time, they will not be buying oil from Russia, and they will go back to Russia after the war is over."

On Thursday, Brent crude futures climbed 0.82% to $62.43 a barrel by 10:31 p.m. ET, while U.S. West Texas Intermediate futures climbed 0.89% to $58.79.

Stock Chart IconStock chart icon

India is one of the biggest buyers of Russian oil. Data from research firm Kpler shows Russia exports about 3.35 million barrels of crude per day, with India taking about 1.7 million and China 1.1 million.

New Delhi has defended those purchases, with Energy Minister Hardeep Singh Puri telling CNBC in July that New Delhi helped stabilize global energy prices and was encouraged by the U.S. to do so.

"If people or countries had stopped buying at that stage, the price of oil would have gone up to 130 dollars a barrel. That was a situation in which we were advised, including by our friends in the United States, to please buy Russian oil, but within the price cap," Puri said.

Russian sales of crude oil have been placed under a price cap by the G7 nations and the European Union since Moscow's 2022 invasion of Ukraine.

That price cap, set at $47.6 per barrel, aims to limit Moscow's revenue from oil exports, constricting the country's ability to finance its war in Ukraine.

Stock Chart IconStock chart icon